Download PDF
Synthesis 2009(4): 620-626  
DOI: 10.1055/s-0028-1083332
PAPER
© Georg Thieme Verlag Stuttgart ˙ New York

Novel Peptide Mimetic Inhibitors of Hepatitis C Serine Protease Derived from Isomannide

Thalita G. Barrosa,b, Sergio Pinheirob, John S. Williamsonc, Amílcar Tanurid, Helena S. Pereirad,e, Rodrigo M. Brindeirod, José B. A. Netod, Octávio A. C. Antunesf, Estela M. F. Muri*a
a Faculdade de Farmácia, Universidade Federal Fluminense (UFF), Rua Mario Viana 523, Santa Rosa, Niterói, RJ 24241000, Brazil
Fax: +55(21)26299588; e-Mail: estelamuri@yahoo.com.br;
b Instituto de Química, Campus do Valonguinho, UFF, Niterói, RJ 24020150, Brazil
c School of Pharmacy, Department of Medicinal Chemistry, University of Mississippi, MS 38677, USA
d Laboratório de Virologia Molecular, ICB, UFRJ, Rio de Janeiro, RJ 21941570, Brazil
e Faculdade de Odontologia de Nova Friburgo, Universidade Federal Fluminense (FOUFF), Nova Friburgo, RJ 28625650, Brazil
f Laboratório de catálise, Instituto de Química, UFRJ, Rio de Janeiro, RJ 21941909, Brazil
Further Information

Publication History

Received 29 August 2008
Publication Date:
27 January 2009 (online)

    Permissions and Reprints All articles of this category

Abstract

Hepatitis C (HCV) infection is a cause of chronic liver disease such as cirrhosis, carcinoma, or liver failure, and the current therapy is effective in only 50% of patients. Serine proteases, which are present in HCV, are the most studied class of proteolytic enzymes­, and are a primary target in the drug development field. In this paper, we describe the synthesis and biological studies of a novel­ class of peptide mimetic compounds as potential HCV serine protease inhibitors.

Key words

peptides - antiviral agent - fused-ring systems - isomannide - hepatitis C